Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beiske, A.G.
Right arrow Articles by Myhr, K.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beiske, A.G.
Right arrow Articles by Myhr, K.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Multiple Sclerosis, Vol. 13, No. 3, 386-392 (2007)
DOI: 10.1177/13524585070130030101

Health-related quality of life in secondary progressive multiple sclerosis

A.G. Beiske

Department of Neurology, University Hospital of Akershus, Lørenskog, Norway

H. Naess

Department of Neurology, Haukeland University Hospital, Bergen, Norway

J.H. Aarseth

Institute of Clinical Neuroscience, Sahlgrenska University Hospital, University of Göteborg, Göteborg, Sweden

O. Andersen

Institute of Clinical Neuroscience, Sahlgrenska University Hospital, University of Göteborg, Göteborg, Sweden

I. Elovaara

Neuroimmunology Unit, Department of Neurology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland

M. Farkkila

Department of Neurology, Helsinki University, Helsinki, Finland

H.J. Hansen

Department of Neurology, Aarhus Hospital, Aarhus University Hospital, Aarhus, Denmark

S.I. Mellgren

Department of Neurology, University Hospital of North Norway, Tromsö, Norway

M. Sandberg-Wollheim

Department of Neurology, University Hospital, University of Lund, Lund, Sweden

P.S. Sorensen

Danish MS Research Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

K.M. Myhr

Department of Clinical Medicine, Section of Neurology, University of Bergen, Bergen, Norway

Common disability scales in multiple sclerosis (MS) are often weighted towards physical disability. Non-motor symptoms such as depression, fatigue and pain substantially influence wellbeing in MS. Health-related quality of life (HRQoL) measures the broader impact of MS and might indicate less obvious disease burdens. We analysed HRQoL, using the Nottingham Health Profile Part I (NHP-I), among 345 secondary progressive MS (SPMS) patients participating in a randomized trial of interferon-ß1a (IFN-ß1a), 22 µg subcutaneously weekly, or matching placebo. The results did not reveal any beneficial effect of IFN-ß1a in any outcome measure. NHP-I sub- and sum scores were compared for 217 population controls and correlated with demographic and clinical disease variables. SPMS patients had lower NHP-I sum and all subscores than the controls. Patients experiencing disease progression reported worse NHP-I sum scores. Increased fatigue, Expanded Disability Status Scale (EDSS) and Arm Index scores were independently associated with reduction in several NHP-I subscores. SPMS patients had significantly lower HRQoL than controls and physical disability (EDSS and Arm Index), disease progression and fatigue strongly influenced this. MS

Key Words: fatigue • multiple sclerosis • quality of life


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?